Generally speaking, those with positive ER and PR have a better prognosis, but the condition of the tumor is related to a variety of factors and needs to be judged in conjunction with other clinical information. ER refers to estrogen receptor and PR refers to progesterone receptor, which are collectively known as sex hormone receptor (HR), and are mainly related to the typing, treatment, and prognosis of malignant tumors, such as breast cancer, endometrial cancer, cervical cancer, and ovarian cancer. ER and PR exist in the nucleus of normal breast cells, endometrial cells, etc. The cancerous transformation of cells will lead to partial and total loss of ER and PR, so generally the higher ER and PR positive rate indicates better tumor differentiation, and on the contrary, those with lower positive rate or even negative rate have poorer tumor differentiation. In addition, positive ER and PR expression implies the presence of endocrine therapy targets, good responsiveness to endocrine therapy, and a better overall prognosis than HR-negative patients. However, the prognosis of the tumor is not only related to HR expression, but also to tumor stage, histological grading, age, and other tumor markers, such as HER2, Ki67, and p53. It is recommended that patients consult with specialists, combine with other clinical examination results to make comprehensive judgment, and reasonably choose the appropriate treatment.